SecBot SecBot

ABVC

ABVC BIOPHARMA, INC.
OTC· Pharmaceutical Preparations· Inc. NV· CIK 0001173313 Biotech & Drug Discovery
$1.04 −0.01 (−0.67%)
Oct 23 4:00 PM ET · prev $1.05
Market cap
$28.0M
Nano cap
1 year
−65.1%
from $2.98 · Oct 24
30 days
−4.6%
from $1.09
52-week range
$0.7110–2.99
−65% from high · low Aug 26
Avg volume 20D
71.8K
Sep 29 spike 183.0K
Short interest
490.3K
≈1.8% of shares · −2.9%
Days to cover
3.6
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 2, 2026
Strongest BEARISH ABVC BioPharma is holding a special meeting on October 28, 2026, to seek shareholder approval for three…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • Short sellersSTEADY

    Short interest −2.9% to 490.3K shares. 3.6 days to cover, ≈1.8% of shares.

  • TrendRANGE

    7% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD374,499$591.7K
NORTHERN TRUST CORPADD48,643$76.9K
UBS Group AGDOUBLED34,123$53.9K
UBS Group AGTRIM1,771$1.7K
NORTHERN TRUST CORPADD32,087$68.3K
UBS Group AGADD2,588$5.5K
SIMPLEX TRADING, LLCNEAR_EXIT196$417.00
VANGUARD GROUP INCDOUBLED267,450$813.0K

Quarterly 13F filings are due 45 days after each quarter ends.

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Aug 11, 2026
Earnings date
ABVC Q2 2026 Earnings Scheduled — 2026-08-11
Aug 4, 2026
Trading halt
Halt Resumed: ABVC — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-03T20:43:59.000Z | Resumed 2026-08-04T13:05:00.000Z
Aug 3, 2026
Trading halt
Trading Halt: ABVC — T1 (News Pending)
ABVC BioPharma, Inc. Cm St | Market: NASDAQ | Code: T1 — News Pending
Aug 3, 2026
Trading halt
Trading Halt: ABVC — T3 (News and Resumption Times)
ABVC BioPharma, Inc. Cm St | Market: NASDAQ | Code: T3 — News and Resumption Times
May 6, 2026
Clinical Trial
PDC-1421 Treatment in Adult Patients With ADHD
Phase Phase 2 — COMPLETED

Short side

FINRA· Sep 30, 2026
490,291
shares short
-2.9%
vs prior settlement
3.6
days to cover
≈1.8%
of shares outstanding
Trading halts
Aug 3, 2026News PendingNot resumed
Aug 3, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 SEC
ABVC BioPharma is holding a special meeting on October 28, 2026, to seek shareholder approval for three proposals: (1)…
DEF 14A — Impact 6/10
Aug 11, 2026 Earnings calendar
ABVC Q2 2026 Earnings Scheduled — 2026-08-11
Aug 4, 2026 SEC
ABVC BioPharma postponed the previously announced distribution of BioKey (Cayman) Inc. ordinary shares, which had been…
8-K — Impact 3/10
Jul 2, 2026 SEC
ABVC BioPharma dismissed auditor Simon & Edward, LLP (S&E) and engaged Kreit & Chiu CPA LLP (KC) as its new…
8-K — Impact 6/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
374,499 shares ($591.7K)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
48,643 shares ($76.9K)

SecBot reports

4 filings · 0 bullish · 3 bearish · 1 neutral
All ABVC filing & press-release reports (4)